Real World Evidence for Management of Severe Bleeding in the Anticoagulated Patient: Impact of Specific Reversal Therapy for Intracranial Hemorrhage and Gastrointestinal Bleeding

July 28, 2023

Real World studies can provide the foundational support necessary for clinicians to effectively manage anticoagulated patients with severe, often life-threatening intracranial and gastrointestinal bleeding. While randomized controlled clinical trials have provided the initial data necessary for appropriate use of reversal agents such as andexanet alfa for Factor Xa associated bleeding, broader studies enrolling thousands of patients, many with significant co-morbidities, are extremely valuable to clinicians. New information regarding the randomized controlled trial ANEXXA-I, which was halted due to andexanet alfa efficacy, provides additional information supporting reversal therapy for severe bleeding.

0 Comments

How Do We Coordinate Care Within Our Hospitals To Improve Outcomes in Hemorrhagic Stroke Patients?

July 5, 2022
Coordinating the necessary care for hemorrhagic patients is complicated- learn the ropes from experts on the UC Stroke Team. "Smoother, faster better" is the name of the game.
0 Comments

Are We Prepared To Manage Anticoagulated ICH Patients or Should We Direct Them Elsewhere?

June 28, 2022
How and where to treat ICH patients- politics, reversal agents, and science all in one podcast!
1 Comments

Why Is the Extended Window Controversial and What Happened With the FDA?

September 7, 2021

Ever wonder why the FDA didn't approve the extended time window for tPA after ECASS3? Listen here to understand the discussion.

2 Comments

The Clock Is Dead - The Reign of Tissue Imaging

August 17, 2021
Mismatch is your friend if you want to treat acute stroke patients beyond 3 hrs. While the clock was once the king, tissue imaging may now define what brain is salvageable and what has been lost. Listen here and see if you agree that the clock is dead in stroke.
0 Comments
RSS
12
Categories
More Entries